Our Team
We are changing the world of molecular diagnostics through easy usage instruments and fast diagnostics
BRANFORD, Conn.–(BUSINESS WIRE)–The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) awarded Tangen Biosciences, Inc. the second phase of a contract to develop a field-deployable Anthrax diagnostic assay and expand the research to an antimicrobial resistance diagnostic assay. The BARDA contract with Tangen Biosciences is, potentially, a 3.5-year project, … Continue reading “Tangen Biosciences Awarded Expanded Second Phase of Contract”
BRANFORD, Conn.–(BUSINESS WIRE)–Tangen Biosciences, Inc., a molecular diagnostic company located in Branford, Connecticut, announced that it has closed a $9 million Series A equity round led by Connecticut Innovations (CI), with participation of current and new stockholders, including VC23, Axiom, and Leading Edge Ventures. The financing proceeds will be used to accelerate the company’s innovative …
October 15, 2018. (Branford, CT) Richard Birkmeyer, PhD, selected as President and CEO of Tangen Biosciences, Inc. Richard “Rick” Birkmeyer, PhD, has been chosen as the President and CEO of Tangen Biosciences, Inc. Before joining Tangen Biosciences, Rick was CEO at CD Diagnostics, Inc. The company developed synovial fluid biomarkers using immunoassay technology which have …
BRANFORD, CONN. (PRWEB) DECEMBER 19, 2017 The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), has awarded Tangen Biosciences a contract to develop a field-deployable Anthrax diagnostic assay. This contract will advance and expand the ability to combat the threat of Bacillus anthracis by utilizing the TangenDxTM Molecular Diagnostic …
The grant will fund the development of specific primers to identify 15 different SNPs in the TB genome that confer resistance to front line TB antibiotics. The drug sensitivity test will be added into the existing Tangen TB assay to create a panel that will include accurate diagnosis of TB along with comprehensive drug sensitivity …